Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick L Locke

Showing results (141-150 of 195) with videos related to

Pageof 20
Sort By:
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Transplantation and Cellular Therapy|July 7, 2023
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell LymphomaNarendranath Epperla, Ambuj Kumar, Syed A Abutalib, et al.
BMJ Oncology|April 1, 2026
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trialsJ Randolph Hecht, Julian R Molina, Kirstin Liechty, et al.
Cancer Cell|August 22, 2025
Lymphoma accelerates T cell and tissue agingRebecca S Hesterberg, Joshua T Davis, Komal J Handoo, et al.
Transplantation and Cellular Therapy|August 30, 2021
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th YearHelen E Heslop, Edward A Stadtmauer, John E Levine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
Pageof 20

Showing results (141-150 of 195) with videos related to

Sort By:
Pageof 20
The New England Journal of Medicine|April 4, 2020
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Javier Munoz, Andre Goy, et al.
Blood Advances|December 5, 2023
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T ConsortiumMichael D Jain, Miriam T Jacobs, Feng Gao, et al.
Journal of Hematology & Oncology|June 6, 2024
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Surbhi Sidana, Leyla Shune, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2022
Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T ConsortiumMiriam T Jacobs, Michael D Jain, Feng Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2023
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell LymphomaJason R Westin, Frederick L Locke, Michael Dickinson, et al.
Transplantation and Cellular Therapy|July 7, 2023
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell LymphomaNarendranath Epperla, Ambuj Kumar, Syed A Abutalib, et al.
BMJ Oncology|April 1, 2026
BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trialsJ Randolph Hecht, Julian R Molina, Kirstin Liechty, et al.
Cancer Cell|August 22, 2025
Lymphoma accelerates T cell and tissue agingRebecca S Hesterberg, Joshua T Davis, Komal J Handoo, et al.
Transplantation and Cellular Therapy|August 30, 2021
Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2021: Looking Forward as the Network Celebrates its 20th YearHelen E Heslop, Edward A Stadtmauer, John E Levine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2020
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T ConsortiumLoretta J Nastoupil, Michael D Jain, Lei Feng, et al.
Pageof 20